LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Today, Nexus Pharmaceuticals announced the launch of Baclofen Injection, USP. This sterile solution is designed for intrathecal administration and serves as a muscle relaxant and antispastic. Baclofen Injection is often used to treat patients with multiple sclerosis, cerebral palsy, spinal cord injuries, and other conditions that result in muscle spasms.
“By adding Baclofen to our portfolio, we continue to lead the charge in minimizing healthcare challenges and improving patient outcomes,” says Omair Ahmed, Chief Operating Officer at Nexus Pharmaceuticals. “This launch is a testament to our tireless efforts to provide essential pharmaceuticals that make a real difference in people’s lives.”
Some benefits of Baclofen Injection, USP include:
- Provides relief of flexor spasms, clonus, concomitant pain, etc.
- Can improve sleep patterns and chronic pain.
- Allows patients who do not respond to or cannot tolerate oral formulations of Baclofen to experience relief despite their limitations.
Baclofen Injection, USP will be available on March 11th, 2024 in individual cartons of 20 mL single-dose vials with a concentration level of 2,000 mcg/mL. Order directly through your wholesaler or from Nexus’ customer service at 888-806-4606.
About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals LLC., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. To learn more about Nexus, visit www.nexuspharma.net.
